CDMO Services
Our proposition to partners in success
Intermediates for CDMO
| S.No | Product Name | CAS No |
|---|---|---|
| 1 | 6-Quinolineacetic acid | 5622-34-4 |
| 2 | 3-fluoro-1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,4-trifluorobut-1-yn-1-yl)-1H-indazole | 68986-76-5 |
| 3 | a-(R)-Cyclopentyl mandelic acid | 64471-45-0 |
| 4 | (R)-1-Methyl-3-pyrrolidinol | 104641-60-3 |
| 5 | 6-chloro-7-fluoro-indoline-2,3-dione | 942493-23-4 |
| 6 | 2-(2,3-dimethoxyphenyl)ethan-1-amine | 3213-29-4 |
| 7 | (1-Amino-2-methylpropan-2-yl)(methyl)amine | 116577-09-4 |
| 8 | 2-chloro-5-methyl-4-phenoxyaniline | 1552471-22-3 |
| 9 | 2-chloro-4-(2-fluorophenoxy)-5-methylaniline | 2680529-02-4 |
| 10 | 3-fl uoro-2-(trifl uoromethyl )benzon itrile | 261951-81-9 |
| 11 | (6-chloro-5-(cyclopropylcarbamoyl)pyridin-3-yl)boronic acid | --- |
| 12 | 1-(3-methyl-2-oxobutyl)-1H-imidazole-5-carbonitrile | 2018317-76-3 |
| 13 | 1-allyl-1H-imidazole-4-carbonitrile | --- |
| 14 | ethyl 5,6-dichloropicolinate | --- |
| 15 | 5-bromo-2-chloro-N-cyclopropylnicotinamide | --- |
| 16 | 5-bromo-2-chloro-N-cyclopropyl-N-methylnicotinamide | --- |
| 17 | 5-bromo-2-hydroxynicotinic acid | --- |
| 18 | 1H-imidazole-4-carbonitrile | 57090-88-7 |
| 19 | 3-cyclopropyl-2-fluorophenol | 2290421-25-7 |
| 20 | 2-(3,4-dihydroxy-5-(trifluoromethyl)phenyl)acetonitrile | |
| 21 | 2-chloro-6-(trifluoromethyl)benzaldehyde | 60611-22-5 |
| 22 | methyl 1-(3-chloropyridin-2-yl)-3-(hydroxymethyl)-1H-pyrazole-5-carboxylate | 960316-73-8 |
| 23 | methyl 3-oxocyclopentanecarboxylate | 32811-75-9 |
| 24 | 4-amino-3,6-dichloro-5-fluoropicolinic acid | 350601-54-6 |
| 25 | 4-(1,1,1,3,3,3-hexafluoropropan-2-yl)aniline | --- |
| 26 | methyl 5,6'-diamino-4'-bromo-4-chloro-2'-fluoro-3'-methoxy-[1,1'-biphenyl]-3-carboxylate | --- |
| 27 | 3-(bromomethyl)-2',4'-dichloro-2-fluoro-1,1'-biphenyl | 1361901-10-1 |
| 28 | 3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)pyridine | --- |
| 29 | 1-(2-chloroethyl)-3-(4-fluorophenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole | --- |
| 30 | 2-(7-(trifluoromethyl)benzo[d][1,3]dioxol-5-yl)acetonitrile | --- |
| 31 | 5-chloro-2-isopropylbenzaldehyde | 1289090-35-2 |
| 32 | 2-bromo-4-chloro-1-isopropylbenzene | --- |
| 33 | N-methyl-4-phenyl-1H-pyrazole-5-carboxamide | --- |
| 34 | 7-(methoxymethyl)-1,3-diazaspiro[4.4]nonane-2,4-dione | --- |
| 35 | 7-(ethoxymethyl)-1,3-diazaspiro[4.4]nonane-2,4-dione | --- |
| 36 | 1,4-dioxaspiro[4.4]nonan-7-ylmethanol | |
| 37 | 3-(3-cyclopropyl-2-fluorophenoxy)-6-methylpyridazine-4-carboxylic acid | |
| 38 | 2-(4-chloro-2,6-dimethylphenyl)acetic acid | 186748-50-5 |
| 39 | 4-(2-bromoacetyl)benzonitrile | 20099-89-2 |
| 40 | ((2R,6R)-6-methyl morpholin-2-yl)methanol | |
| 41 | Cyanotemozolomide (or) 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carbonitrile | 114601-31-9 |
| 42 | 5-isothiocyanato-3-(trifluoromethyl)picolinonitrile | 951753-87-0 |
| 43 | 7-methyl xanthine | 69-89-6 |
| 44 | bis ((penta chloro phenyl (thio (Zinc)) | 117-97-5 |
| 45 | (2S,3R)-3-(2,4-difluorophenyl)-3-hydroxy-2-methyl-4-(1H-1,2,4-triazol-1-yl)butanethioamide | |
| 46 | tert-butyl 3-bromo-2-hydroxybenzylcarbamate | 2378271-30-6 |
| 47 | 3-(3-chloro-2-fluorophenoxy)-6-methylpyridazine-4-carboxylic acid | 2435607-79-5 |
| 48 | 4-(3-oxobutyl)phenyl acetate | 3572--06-3 |
| 49 | (S)-2-(1-phenylethoxy)acetic acid | 287400-90-2 |
| 50 | Bromo OTBN | 114772-54-2 |
| 51 | Methyl (2S)-3-(4-aminophenyl)-2-(2,6-di chloro benzamido)propionate | 554419-04-4 |
| 53 | 2-(2,3-dimethoxyphenyl)-N,N-dimethylethanamine | 3494--01-7 |
| 54 | 2,4-difluoro-3-(methylthio)benzoic acid | 169310-07-0 |
| 55 | 2-(2,4-difluoro-3-(methylthio)phenyl)-4,4-dimethyl-4,5-dihydrooxazole | ---- |
| 56 | 2-(4-fluoro-2-methyl-3-(methylthio)phenyl)-4,4-dimethyl-4,5-dihydrooxazole | ---- |
| 57 | 3-Carbamoyl-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridin-1-ium chloride | 23111-00-4 |
| 58 | Benzyl ((S)-2-((tert-butoxycarbonyl)amino)-4-phenylbutanoyl) -L-leucyl-L-phenylalaninate | 868540-15-2 |
| 103 | 2,3-bis(2-hydroxyethyl)phenol | 199391-75-8 |
| 104 | 2,3-dihydro-4-vinylbenzofuran | |
| 105 | 2-(5-Bromo-2-methylbenzyl)-5-(4-fluorophenyl)thiophene | 1030825-20-7 |
| 106 | 2-(4-Flurophenyl)Thiophene | 58861-48-6 |
| 113 | 2-chloro-4-(2,2,2-trichloroethyl)-3,3-dimethylcyclobutanone | |
| 114 | 3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylic acid | |
| 132 | 4-((1-Cyanocyclobutyl)amino)-2-fluoro-N-methylbenzamide | 915087-26-2 |
| 133 | 4-amino-2-fluoro-N-methylbenzamide | 915087-25-1 |
| 137 | 5-bromo-1-(2-fluoro-6-(trifluoromethyl)benzyl)-6-methylpyrimidine-2,4(1H,3H)-dione | 830346-48-0 |
| 138 | (S)-tert-butyl (2-(5-bromo-3-(2-fluoro-6-(trifluoromethyl)benzyl)-4-methyl-2,6-dioxo-2,3-dihydropyrimidin-1(6H)-yl)-1-phenylethyl)carbamate | |
| 139 | 3,6-dichloropyrazine-2-carbonitrile | 356783-16-9 |
| 140 | 3-amino-6-chloropyrazine-2-carbonitrile | |
| 141 | 5-chloropyrazin-2-amine | 33332-29-5 |
| 142 | 3-bromo-5-chloropyrazin-2-amine | 76537-18-3 |
| 143 | (S)-benzyl 2-amino-3-(3-(methylsulfonyl)phenyl)propanoate | 1270093-99-6 |
| 144 | 5,7-dichloro-2-trityl-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid | 1289646-93-0 |
| 145 | benzofuran-6-carboxylic acid | 77095-51-3 |
| 146 | (2RS)-2-(4-Chlorobenzoylamino)-3-(2-oxo-1,2-dihydroqunolin-4-yl)propanoic acid | 90098-04-7 |
| 147 | 2,3-dihydrobenzofuran-5-carbaldehyde | 55745-70-5 |
| 148 | (E)-ethyl 3-(2,3-dihydrobenzofuran-5-yl)acrylate | 196597-65-6 |
| 149 | (E)-2-(6,7-dihydro-1H-indeno[5,4-b]furan-8(2H)-ylidene)acetonitrile | 196597-79-2 |
| 150 | 6,7-dihydro-1H-indeno[5,4-b]furan-8(2H)-one | 196597-78-1 |
| 151 | 1-(6-Methylpyridin-3-yl)-2-[(4-methylsulfonyl)- phenyl] ethanone | 221615-75-4 |
| 152 | N-[(2Z)-2-Chloro-3-(dimethylamino)- 2-propenylidene]-N-methylmethanaminium hexafluorophosphate | 291756-76-8 |
| 153 | 1-(4-(Methylsulfonyl)phenyl) ethanone | 10297-73-1 |
| 154 | 2-(4-(Methylsulfonyl)phenyl) acetic acid | 104-01-8 |
| 155 | Methyl 6-methylnicotinate | 5470-70-2 |
| 160 | 6-cyclohexyl-4-methyl-2H-pyran-2-one | 14818-35-0 |
| 161 | 4-(3,5-Dichlorobenzamibo)-3-hydroxybenzoic acid | 1184581-58-5 |
| 162 | Methyl 2-amino-2-(2-chlorophenyl)acetate | 141109-13-9 |
| 163 | (S)-Methyl 2-amino-2-(2-chlorophenyl)acetate tartaric acid | 141109-15-1 |
| 164 | (S)-Methyl 2-amino-2-(2-chlorophenyl)acetate | 141109-14-0 |
| 165 | 2-(Thiophen-2-yl)ethyl 4-methylbenzenesulfonate | 40412-06-4 |
| 166 | (S)-Methyl 2-(2-chlorophenyl)-2-((2-(thiophen-2-yl)ethyl)amino)acetate hydrochloride | 141109-19-5 |
Our Value Proposition
Partners in Success
We work as an extension of our partners, providing end-to-end solutions from concept to commercial scale. Our commitment is to deliver innovative, compliant, and cost-effective manufacturing solutions that support your growth.
Technical Excellence
Regulatory Compliance
Cost Competitive
Timely Delivery
Let’s Grow Together
A proven track record in the development of practical, safe, highly economical and scalable routes to a variety of APIs and key Intermediates in Grams-Kilos-Tons
Our Competitive Advantages
1
Innovation
Cutting-edge process development and optimization capabilities for complex APIs.
2
Quality
Stringent quality standards and regulatory excellence across all operations.
3
Expertise
Proven capabilities in complex molecule synthesis, process optimization.
4
Scalability
Multi-unit manufacturing network with capacity to scale from pilot to commercial.
Our Track Record
Proven Delivery, Trusted Partnerships
For over two decades, we have scaled complex molecules from lab to commercial production. Our portfolio of successful CDMO programs, customers across 100+ countries and consistently high on-time delivery reflect the reliability our partners count on, and why most of them return to us.
VIRUPAKSHA CDMO DIVISION
Contract Development and Manufacturing Organization
Excellence in Pharmaceutical API & Specialty Chemical Manufacturing
Why Choose Us for CDMO/CRAMS
Regulatory & Compliance Excellence
- USFDA, PMDA, EDQM Approved
- GMP Compliant Across Jurisdictions
- ISO 9001:2015 & ISO 14001 Certified
- Regulatory Documentation Support
- Pre-Approval Inspection (PAI)
- Batch Record Management Systems
Technical Capabilities
- Multi-step Synthesis Routes
- Scale-up from Lab to Commercial
- Process Optimization & Validation
- Analytical Method Development & Validation
- Environmental Assessment (ICH Q3C)
- Green Chemistry & Sustainability Practices
Therapeutic Area Expertise
- CNS & Neuro-active Compounds
- Oncology & Specialty APIs
- Anti-infectives & Antivirals
- Cardiovascular & Metabolic Compounds
- Complex & Hazardous Chemistry
- Chiral & Specialty Synthesis
Capacity & Throughput
- Multi-Unit Manufacturing Network
- Kg to Ton Scale Production
- Dedicated Campaign & Shared Facility Options
- Quick Turnaround on Development Projects
- Flexible Scheduling & Availability
- High Throughput Capabilities
Quality & Cost Advantage
- Competitive Pricing Models
- No-Cost Failure Rate < 2%
- Just-In-Time Supply Chain
- Cost Reduction Through Innovation
- Transparent Pricing & Costing
- Payment Terms Flexibility
Confidentiality & IP Protection
- Confidentiality Agreements (NDA)
- Single-Sourcing Capability
- Know-How & Process Confidentiality
- Segregated Manufacturing Areas
- Restricted Access & Security Protocols
- Data Room & Documentation Systems
What We Do
Partnerships
Collaboration with innovators and generic API companies for development and seamless technology transfer.
Process Validation
Expertise in process optimization, process validation and analytical method validation for complex molecules.
Regulatory Support
USFDA & PMDA-approved facility. Ensuring complete regulatory compliance and documentation.
Cost Efficiency
Competitive pricing models with stringent quality standards and on-time delivery.
